Table 3.
Ongoing Treg-based clinical trials in autoimmunity.
| Study ID | Phase | Intervention | Source | Dose | Drugs | Condition | Status | Location |
|---|---|---|---|---|---|---|---|---|
| NCT03011021 | I/II | UCB-polyclonal Treg | Umbilical cord blood | 1-5x106/kg | Insulin Liraglutide |
T1DM | Recruiting | Hunan, China |
| NCT03239470 | I | Autologous polyclonal Tregs | NA | Cohort 1: 1x108 cells Cohort 2: 2.5x108 cells |
NA | Pemphigus | Recruiting | Kentucky, United States |
| NCT02691247 | II | Autologous polyclonal Tregs | NA | NA | NA | T1DM | Active, not recruiting | United States |
| NCT02704338 | I/II | Autologous polyclonal Tregs | Peripheral blood | 10–20x106 cells/kg | NA | Autoimmune hepatitis | Not yet recruiting | Nanjing Medical University, China |
| NCT03185000 | I/II | Autologous polyclonal Tregs | Peripheral blood | 0.5–1, 3–5 and 8–10 × 106 cells/kg | NA | Crohn’s Disease | Not yet recruiting | King’s College London |
| NCT02772679 | I | Autologous polyclonal Tregs + IL-2 | NA | Cohort 1: 3x106 cells Cohort 2: 20x106 cells |
NA | T1DM | Active, not recruiting | California, United States |
| NCT02932826 | I/II | UCB-Treg | Umbilical cord blood | 1–5x106/kg | Insulin | T1DM | Recruiting | Hunan, China |
UCB-Treg, Regulatory T cells expanded from umbilical cord blood; Type 1 Diabetes Mellitus, T1DM; NA, Not available.